MoneyWorks4Me

Sun Pharmaceutical Industries informs about press release

21 Jul 2025 Evaluate

Sun Pharmaceutical Industries has informed that it enclosed a copy of the press release by Sun Pharmaceutical Industries (together with its subsidiaries / affiliated companies, ‘Sun Pharma’) about ‘Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint’.

The above information is a part of company’s filings submitted to BSE. 

Peers
Company Name CMP
Sun Pharma. Inds. 1784.25
Dr. Reddys Labs. 1197.35
Cipla 1335.60
Lupin 2012.00
Zydus Lifesciences 1141.00
View more..